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Abstract
The fact that there is very little if any overlap between the genes of different prognostic signatures for early-discovery breast
cancer is well documented. The reasons for this apparent discrepancy have been explained by the limits of simple machine-
learning identification and ranking techniques, and the biological relevance and meaning of the prognostic gene lists was
questioned. Subsequently, proponents of the prognostic gene lists claimed that different lists do capture similar underlying
biological processes and pathways. The present study places under scrutiny the validity of this claim, for two important
gene lists that are at the focus of current large-scale validation efforts. We performed careful enrichment analysis,
controlling the effects of multiple testing in a manner which takes into account the nested dependent structure of gene
ontologies. In contradiction to several previous publications, we find that the only biological process or pathway for which
statistically significant concordance can be claimed is cell proliferation, a process whose relevance and prognostic value was
well known long before gene expression profiling. We found that the claims reported by others, of wider concordance
between the biological processes captured by the two prognostic signatures studied, were found either to be lacking
statistical rigor or were in fact based on addressing some other question.
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Introduction
Technological advances made during the last decade have
allowed measurement of enormous amounts of molecular data
from a tumor tissue resected from a particular subject. The main
challenge of modern cancer research is bridging the gap between
these data and clinically significant questions that need urgent
answers, such as prognosis and prediction of response to therapy.
The first issue, of prognosis, is highly relevant, since it is used to
decide whether to subject a patient to chemotherapy. This
decision is extremely important for the individual as well as for
society for three main reasons. First, nearly all available
chemotherapy is detrimental to the patient, since it adversely
affects healthy tissue as well as the malignant one, at which it is
aimed. Second, some of the side effects, even if they do not have a
direct impact on the patient’s physical well-being, may cause
considerable psychological damage and hardship. Finally –
chemotherapy is extremely expensive.
It is well known that for many cancers prognosis and the need
for therapy may vary widely; while in some cases surgery and
adjuvant radiotherapy suffice to eradicate the disease, other
tumors are very aggressive, will recur, metastase and kill the
patient. While aggressive tumors call for chemotherapy, overtreat-
ment of ‘‘good outcome’’ patients by administering unneeded
chemotherapy is, unfortunately, very common. This is the case
particularly in breast cancer, where increased awareness has
brought, through regular frequent checkups, a considerable
increase in the number of early discovery cases, of small tumors
of low stage and grade.
It is believed that the currently accepted clinical-pathological
criteria for administering chemotherapy gives rise to overtreat-
ment of a very large fraction of early discovery breast cancer
patients. Therefore, there is an acute need for reliable biomarkers
that can, on the basis of measurements done on the primary tumor
tissue, differentiate poor from good outcome.
A large number of methods have been introduced to generate
biomarkers from available molecular information (in particular
from gene expression microarray data – see [1,2,3,4] for reviews).
Two prognostic platforms based on expression signatures are
commercially available: OncotypeDx, based on a 21-gene
signature measured on paraffin-embedded samples by polymerase
chain reaction (PCR) [5], and Mammaprint, the 70-gene
‘‘Amsterdam signature’’ measured by a microarray [6,7,8,9].
Considerable criticism has been raised about the following
aspects of several proposed signatures: lack of robustness, various
statistical and machine-learning related problems, low success
rates for the cases that are hard to prognosticate by existing
methods, and lack of biological meaning of gene lists, that were
obtained without biological guidance.
The first criticism, concerning the statistical validity and
robustness of the reported gene lists, focuses on the fact that in
many cases the reported signatures were derived and tested in only
one particular way, which was arbitrarily selected out of many
equally legitimate ones. For example, one can split the samples
into a training set and a test set in a combinatorially large number
of ways. Hence the entire analysis, including training, gene
selection and testing, can be repeated many times, using the same
data, but splitting differently the samples into training and test sets.
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analysis, and by performing many such repeats, one can generate
distributions of various quantities of interest. In particular, one can
calculate for each split the success rate, defined as the fraction of
successful predictions of outcome on the test set, and estimate the
distribution of the success rates by repeating the analysis many
times. Once this distribution is known, one can estimate the
probability to find a success rate as good as, or better, than the one
reported in the actual published study (for which the analysis was
repeated). When this was done [10,11], the results of many studies
have been demonstrated to be ‘‘overoptimistic’’ [11]; the success
rate that was actually reported had a much lower than acceptable
probability of being observed. The overoptimistic reported success
rates of many studies were explained by falling into various
statistical pitfalls [2,12]. These include severe overtraining [2], due
mainly to ‘‘information leak’’ which has been explicitly identified
in a number of cases [2,13]. The term information leak refers to
allowing usage of any information about the test set during the
training phase. Another issue concerns the prognostic lists of genes
(which are the ones that are actually placed on a prognostic device
[7]). The genes that appear in the prognostic list of a particular
study were selected by ranking all the tested genes (for example, on
the basis of the correlation of their expression values (measured
over the training samples) with outcome. These lists were shown to
lack robustness [10] for the sample sizes used [14,15]; i.e. the
prognostic gene lists changed almost completely when the
procedure was repeated. It has been shown [14,15] that if a
training set of ,100 early breast cancer samples is used to rank
,10,000 genes (by their correlation with outcome), and the ,100
top genes are selected as the prognostic set, repeating the
procedure (with a different set of training samples) will produce
a new gene list, whose overlap with the first one is typically 2–3%.
Since the different gene lists obtained even from the same
particular study are very unstable against repeating the analysis,
one clearly expects even less overlap between lists produced by
different studies (in which different patients, different microarray
facilities and even different platforms were used). In response to
this criticism it was stated that if two divergent lists provide
concordant prognostication and acceptable success rates, one
should not care about their lack of robustness [16]. This response
was countered, however, by criticism raised against the criteria
that were used to assess the success rates of several expression-
based classifiers [17], and various publications questioned whether
they actually performed better than either a single-gene based
classifier [18] or one that uses classical clinical and pathological
indicators [19,20]. The issue of concordance [21] or lack thereof
[17,22] between different prognostic signatures was also debated.
The points of criticism described above address either technical
issues that concern the standard machine-learning approaches
taken by most derivations of prognostic signatures, or the clinical
utility of the resulting classifiers. In the present study we focus on a
third type of criticism, directed at the lack of biological meaning of
various prognostic signatures. Some signatures [5,23,24,25,26,27]
did use biological and clinical knowledge to assemble their
predictive genes. We did not consider the Oncotype DX
recurrence signature [28], which was constructed by carefully
picking genes from relevant pathways (and therefore indeed,
capture many pathways); the P53 signature [24], BMI1 signature
[27] and wound response signature [23,29], each of which was
constructed to capture a specific pathway, as their names suggest
(and therefore indeed mainly capture the desired pathway); or the
genomic grade signature [30] that was constructed specifically to
capture histological grade (and was found to include mostly
proliferation-related genes [31]). Our focus is on prognostic gene
lists which were derived using the ‘‘top-down’’ approach as defined
in [32], that is, either using no biological guidance at all for feature
selection and training – e.g. the Amsterdam signature [7], or using
very minimal biological input, such as for the 76-gene Rotterdam
signature [33], which treated ER+ and ER2 breast cancers
separately.
According to the critics, these prognostic gene lists lack clear
biological interpretation and probably contain no biologically
relevant discovery. In response to this criticism it was claimed by
some [34] that the biological processes that were represented by
the activities of the genes on such divergent lists did, in fact, exhibit
considerable similarity. If correct, this claim gives one more reason
why one should not worry about the fact that the gene lists of
different studies had no overlap; furthermore, this would also
answer the criticism regarding biological meaning.
The claim that divergent gene lists from different studies do
reflect the activities of similar cancer-related pathways and
biological processes seems to be advocated and accepted by many
[1,9,15,21,34,35,36]. Only a few studies [37,38,39,40] have,
however, actually tried to substantiate these claims in a
quantitative manner. The aim of our study is to test the validity
of these claims in a way which we believe is conceptually and
statistically sound.
In what follows, we first present the guiding principles that must
be adhered to in order to test properly these claims, and then we
review critically the studies mentioned above. Next we present our
results obtained when the analysis is carried out for two important
signatures [7,33] according to our guiding principles. We conclude
that the only biological processes and pathways that are
significantly represented by both these signatures are cell
proliferation and its variants.
The guiding principles of the present study
Our aim here was to test critically the claims that two different
machine-learning based prognostic gene lists capture similar
biological processes. To this end we examined the two most
established outcome prediction signatures, the 70 gene list of van’t
Veer et al. [7] and the lists defined by Wang et al. [33], both the 60
gene ER+ signature and the complete 76-gene list. We have
chosen these two signatures as they were learned independently
and without forcing specific biological pathway-based knowledge.
We adopted the following guiding principles in designing our
test:
1. Use only the genes that actually appear in the prognostic lists.
2. Identify over-represented biological processes by means of
enrichment analysis.
3. Address the problem of false discoveries generated by multiple
comparisons that are made, but take into account all the
dependencies and nested structures present in the ontologies
used.
4. Use more than one gene ontology, to minimize dependence on
incomplete or deficient class assignments.
The rationale for the first principle is the following. As stated
above, our aim is to test, in a statistically correct way, the claim
that was voiced by proponents of the proposed prognostic lists,
that different lists do capture the same biological processes. To test
this claim, one is not supposed to use larger gene lists, which could
have been derived from the same experiment by some other
means. We are neither claiming that gene expression cannot
possibly capture important and biologically relevant prognostic
information, nor are we attempting to demonstrate how one could,
in principle, capture such information.
Pathway Overlap of Breast Cancer Prognostic Lists
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reflect similar deregulation of a few common relevant pathways, but
it remains to be proven that this similarity is captured in the actual
proposed gene lists. In that regard it is worth mentioning that when
standard machine-learning methods are used to select features
(genes)for a classifier, thenumberof selected featurescannot exceed
significantly the number of samples that happened to be available
for training [41] (at the time when the study was first performed and
the gene lists were selected). Otherwise the classifier is trained to
recognize the noise in the particular training set used, and will fail
on any test set (since while the true ‘‘signal’’ is the same in the
training and test sets, the noise is completely independent). This
limitation might restrict the selected number of genes and produce
lists of selected genes that are too short to capture the necessary
biological processes. Two possible ways to overcome this are
producing much longer gene lists (for which much more training
samples must become available), or use biologically relevant
knowledge based considerations to select the predictive genes.
The second principle states that a generally accepted method
[42] be used to assess enrichment of a pathway or biological
process by the prognostic list.
The third principle – the necessity for taking into consideration
the false discoveries [43,44] that arise when multiple comparisons
are made - cannot be overemphasized [41]. A problem arises
when one performs enrichment analysis of GO (gene ontology)
terms [45], such as Biological Processes (GOBP). When the
number of GO terms is taken as the number of independent tests,
it is likely that not a single term will pass any of the available
procedures [46] that control the FDR. The reason is that because
of the nested and overlapping structure of the ontology, the many
terms tested are not independent and hence the standard methods
that control the FDR are much too stringent [47,48] (to
understand this point, imagine that in fact we have one single
term which for some reason is repeated 1000 times – while only a
single test was performed, naively we may think that 1000
hypotheses were tested). The trivial resolution of this problem, of
ignoring multiple testing altogether and make no attempt to
control the FDR, goes to the opposite extreme and is way too
permissive, generating a very large number of false positive
apparently enriched GO terms.
We present and compare three ways to deal with the problem of
multiple comparisons. The first is to apply the standard Benjamini-
Hochberg procedure [43] to control the FDR, ignoring the nested
structure of the ontologies. We show that this procedure, which is
probably too stringent, finds almost no commonly enriched
biological processes or pathways. The second and third are two
different ways, explained in detail in the Methods section, designed
to deal with multiple comparisons while taking the dependencies
and nested structure of the ontologies into account.
The fourth principle stems from the known fact that ontologies
are far from being perfect, and probably contain some incorrectly
assigned genes; testing a claimed enrichment for more than one
ontology or database is prudent.
The manner in which each of these points is implemented is
explained in detail in the Methods section below.
Brief review of previous work
The abstract of Yu et al. [40] states that ‘‘We show that
divergent gene sets classifying patients for the same clinical
endpoint represent similar biological processes …’’. They
addressed this issue indirectly by using expression data of 344
early discovery breast cancer patients; the same analysis was done
separately for the ER+ and ER2 cases. 80 samples were selected
at random as training set; Cox regression analysis was performed
to identify the 100 genes whose expression was most correlated
with distant metastasis-free survival time. These ‘‘top 100’’ genes
were analyzed for enrichment of 304 GOBP (selected, using some
arbitrary thresholds, from the total list of GOBP). The enrichment
analysis was done as follows: hypergeometric p-values were
calculated (Fisher’s exact test) for over-representation of the genes
that belong to a GOBP among the 100 ‘‘top genes’’, and if the
number of genes exceeded one and the p-value was less than 0.05,
the GOBP was declared enriched. No correction for multiple
comparisons (of either genes or GOPB) was used, and no special
treatment to the GOBP dependence (due genes that appear in
several GOBPs) was offered. This analysis was repeated 500 times,
yielding 500 lists of enriched GOBP. The 20 GOBP that had the
highest number of appearances were assembled, for ER+ and
ER2, yielding 36 ‘‘core pathways’’ (4 appeared on both lists).
Finally, several published prognostic gene lists were analyzed for
enrichment among the 304 GOBP and among the 36 core
pathways, and using the hypergeometric distribution, significant
overrepresentation of the core pathways was reported.
This analysis is too permissive mainly because no FDR
correction for multiple comparisons was used at all. Moreover,
several arbitrary and unjustified thresholds were used for selection
of GOBP to be tested and for identification of enriched GOBP; the
sets of enriched GOBPs obtained for each pair of prognostic gene
lists were not compared directly, but each was compared to the list
of core pathways defined above; only one database of biological
pathways and processes was used for the study.
Shen et al. [38] have followed similar guidelines to those we
suggest. They actually don’t find a statistically significant number
of pathways common to the Wang and van’t Veer lists (this fact is
not emphasized, but see Figure 1 of their paper). Moreover, the
statistical significance of the overlaps they report is due to an
unusual definition of the p-value. Namely, if they find that the
tested prognostic list contains k genes from a pathway, they
estimate the p-value as the probability that a random gene list will
contain more than k genes from the pathway- p(x.k), instead of
using the standard definition, i.e. the probability to find k or more
than k such genes- p(x$k). These two probabilities are nearly the
same for most situations, but can be quite different when the list is
very short (small k), as is the case here, where often k=1. Table 4
in their paper shows what appears to be significant overlap
between several signatures, but in fact there is only one single gene
of the 70 gene list that belongs to each of the ‘enriched’ pathways.
Given that 50 genes from the 70 are annotated, chosen out of
11342 genes on the chip (the ‘‘population’’), and that, for example,
the RECK pathway (one of the five presented as significantly over-
represented and shared in Table 4) has 8 genes from the
population, a naı ¨ve hypergeometric test will conclude a p-value
of 0.035, while Shen’s measure will indicate a much higher
significance, of 5.24*10-4. Checking the hypothesis for all probes
(not just annotated ones) will increase the p-value further. The
naı ¨ve hypergeometric high p-values will not pass a reasonable
FDR on the 552 hypotheses checked. The other 4 pathways also
have only one gene among the 50, and since these pathways
contain more genes than RECK, their p-values will only be bigger.
Even if one chooses to ignore the 70 gene list, and look for
pathways common only to the three other signatures checked in
the paper, only the breast cancer estrogen signaling pathway is
found to be over represented in all. Repeating this analysis using
the standard definition of the p-value, we found that for the 70
gene list no pathway passes at any reasonable FDR, and even if we
ignored the 70 gene list, still only the breast cancer estrogen
signaling pathway was over represented in all the other three
signatures tested.
Pathway Overlap of Breast Cancer Prognostic Lists
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convergence of the signatures directly, but instead aimed at
offering a new, pathway based predictor. In order to do so they
have used a large number of tumor expression profiles measured
by the Affymetrix 133A platform, started from seven published
signatures and used them to create enlarged signatures. These
contained all the genes correlated to the original signature,
revealing large gene clusters that differentiated good from bad
outcome. A careful pathway analysis discovered common
pathways which were then used to build new, more promising
predictors. In our context, however, one must be careful not to
deduce from this study that there is biological agreement between
the actual seven signatures they studied, as their analysis was done
on highly enlarged gene lists.
Sole et al. [39] have tested different signatures of different
cancers, including breast cancer signatures [5,29,49,50,51,52], by
two main approaches. The first was to check for overrepresenta-
tion of transcription factor targets as predicted by motif analysis
and chip experiments. The second was to check on a few datasets
for correlations between the signature genes and the various
pathway genes. The first approach identified targets of E2F and
ER, as well as cell cycle genes, to be common to many of the
signatures. Note that E2F is a major proliferation regulator and
many of its targets correlate with proliferation rate. They have
raised also the possibility that AHR, MYB and MYC targets are
overrepresented in a few of the signatures. The second approach
identified mitosis and possibly immune response as related to some
of the breast cancer signatures on the examined data. Note that
the second approach may reflect the prognostic potential of the




van’t Veer’s signature was developed based on ,5000 probes
(we reproduced a list of 5159 probes) from the Rosetta Hu25K
microarray, Wang’s signature was developed based on 17816
probes from the Affymetrix U133A microarray. These probes
were selected by filtering out probes with low signal, and hence
were the actual candidates for the signature, and therefore we
chose these lists as the background references.
The Hu25K probes were matched to known genes by their
sequences using BLAST [53], and mapped into official gene
symbols. We used Affymetrix’s mapping of the U133A probe sets
to gene symbols. For TANGO analysis probes were converted to
Entrez GeneID using MatchMiner [54]. Since not all probes
capture a recognized gene with an official gene symbol, and some
probes capture more than one gene, the actual lengths of the lists
are slightly different than the corresponding list of probes. This,
however, does not affect the enrichment analysis as probes with no
recognized official gene symbol also have no known annotations.
The gene lists of the van’t Veer and Wang signatures are listed in
Table S1.
Testing for significant pathway enrichment of each list
with standard FDR control
The pathway databases used for our analysis are the Gene
Ontology Biological Process [45] annotations, (as downloaded
from [55]) and MSigSB C2 Canonical Pathways database (version
2.5) [56], which integrates 12 different pathway databases. When
referring to a GOBP annotation we refer to all the genes in this
annotation together with all the genes of all the descendent
annotations. Only annotations that had at least one gene in the
relevant background were considered. When considering the size
of the annotation, only genes that appear in the relevant
background were counted.
For every individual gene list (signature) studied we tested
enrichment by genes that belong to a particular biological process
or pathway. Enrichment of annotations were computed by Fisher’s
exact test, using for each signature as background reference the
gene population of the original experiment from which the
signature was derived (i.e. genes from the corresponding chip that
have passed the initial filtering), and correcting for multiple testing
by standard control of the FDR [43], without taking the nested
dependencies of the GO annotations into account.
More accurate control of multiple hypotheses, using
resampling
One might claim that using the standard methods to control the
FDR is too strict (mainly due to the dependencies between the
pathways). Alternative approaches were suggested to test for
annotation enrichments, which were claimed to be less stringent
than the standard control of FDR, while still offering correction for
testing multiple hypotheses. TANGO [48] performs functional
enrichment tests that fully account for multiple testing, using a
simple resampling algorithm. The aim is to assess the significance
of the enrichment of a gene set T in the different biological
processes Ai of an ontology A. First, TANGO computes the
hypergeometric p-values pi of T against all the processes. To
determine (in a way that takes multiple testing into account) which
of these is significant (at say 5% level), TANGO calculates the
empirical background distribution of the best p-values obtained for
each one of a large number of randomly generated gene lists (of
the same length as T). Finally, the corrected p-value of each
process Ai is determined as the probability to do better, using the
background distribution. This way all the relations among the
biological processes of the ontology are preserved.We have used
the EXPANDER [57] implementation of TANGO to test for GO
annotation enrichments in all three lists (Wang 60, Wang 76, and
van’t Veer 70), and determined the threshold on the corrected p-
values one needs to use in order to have even a single enriched
process shared by van’t Veer and one of the Wang lists.
Correcting pathway overlap for multiple testing by
assessing the significance of shared processes
At the opposite end of the spectrum of stringency one is ignoring
the problem of multiple hypotheses and simply looks for biological
processes that passed some threshold on the enrichment p-value for
both gene lists, such as performing Fisher’s exact test [42] and taking
only p-values smaller than 0.05. Clearly, since the set of biological
processes that satisfied this criterion was derived neglecting
completely multiple testing (e.g. of testing many biological
processes for enrichment), this procedure is too permissive. To
estimate the significance of the fact that a biological process passed
this criterion in a way that corrects for multiple testing, we devised
a random model to generate a relevant background distribution,
which takes into account the real dependences between the
pathways and biological processes. Two random lists, L60 and
L70, containing 60 and 70 genes, were generated from the
respective lists of probes from the chips used by van’t Veer and by
Wang. We then preformed Fisher’s exact test between the genes
that correspond to the selected probes of each of the two lists and
every biological process (or pathway), and determined the number
x of processes with enrichment p-value smaller than some
threshold q (we used q=0.05, 0.10 and 1.0), for both L60 and
L70 (as opposed to TANGO which estimates enriched pathways for
Pathway Overlap of Breast Cancer Prognostic Lists
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histogram of x, we constructed a background distribution P(x=k),
estimating the probability to get by chance k processes with hyper-
geometric enrichment p-value,q for both random gene lists.
Hence, the significance of observing c biological processes or
pathways for which both the Wang and van’t Veer gene lists are
enriched at this level, is simply estimated by P(x.=c). Note, that
just like in the actual process of learning the signatures, probes that
do not map to known genes with known annotations could be
selected, and therefore the effective length of the gene list is usually
smaller.
Results
Testing for significant pathway enrichment of each list
with standard FDR control
In order to check rigorously the claims of convergent biological
pathways and processes for different gene lists, we examined (see
Methods) the two most established outcome prediction signatures,
the 70 gene list of van’t Veer et al. [7] and Wang et al’s ER+
signature [33].
We have chosen the richest, well accepted annotation database,
the gene ontology biological process (GOBP) database [45] as the
major list of pathways, and repeated the analysis with two more
lists, for the sake of completeness (see below).
Only a single process, DNA Replication, passed FDR in both
signatures, at a very permissive level of 0.31. Raising the bar to
FDR=0.53 gave rise to the microtubule cytoskeleton organization
pathway, and with even more permissive FDR only two closely
related annotations emerged - ‘microtubule-based process’ and
‘DNA-dependent DNA replication’. This indicates that probably
both signatures capture some aspects of cell cycle and proliferation.
It is worth mentioning that the well accepted DAVID annotation
tool [58,59] does not find any enriched pathway in any of the
signatures, which passed FDR of 0.9, other than organelle
organization and biogenesis in Wang’s signature (q=0.36).
We repeated the analysis for a shorter list of GOBPs along the
lines of Yu et al. [40] who tested only those 304 GOBPs that had
representative probe sets for at least 10 of their genes on the
U133A chip. We found 1373 such GOBPs and repeated our
analysis limited to this list (we believe that the discrepancy between
304 and 1374 is due to the fact that Yu et al used a very early
version of the GO database). Next, we also examined the MSigDB
canonical pathways database [56], collecting metabolic and
signaling pathways from 12 online pathway databases. Further-
more, we repeated the analysis for the entire signature of Wang (76
probe sets). All these additional comparisons yielded even less
common pathways than the original one. The full results of all the
pathways that passed FDR of 0.75 in any one of the three
databases are shown in Table S2. Few more details can be found
in the Methods section.
More accurate control of multiple hypotheses, using
resampling
TANGO [48], a resampling based method for pathway
enrichment analysis (see Methods), did not find any pathways
with p-value smaller than 0.48, see Table S2 for annotations with
less significant p-values (DNA Replication was found in all
signatures, but with a p-value higher than 0.8).
Correcting pathway overlap for multiple testing by
assessing the significance of shared processes. Using the
‘‘p-value smaller than 0.05’’ criteria with p-values obtained by
Fisher’s exact test of both signatures (see Methods), gave rise to 18
common pathways, most of which were related to cell cycle.
Raising the allowed p-value threshold to 0.1 discovers 10 more
pathways of different contexts, as also shown in Table 1.
Since this overlap was derived neglecting multiple testing
completely, it is too permissive. We estimated the significance of
this overlap using a random model (see Methods) to generate a
relevant background distribution that takes into account also the
real dependences between the pathways and biological processes.
This analysis finds that the number of common Biological
Processes (derived without any FDR control) that we found for
the real lists was significantly higher than the number for random
signatures- we calculated a p-value of 0.015 to get the observed
overlap for threshold of p,0.05 (and 0.068 for p,0.1), showing
that indeed both signatures capture some common essence. As
before, the process was repeated for the reduced GOBP list and
MSigDB, as well as for Wang’s complete 76 genes signature. The
results of the analysis were similar, as shown in Table S3.
What common pathways are really present, other than
proliferation?
The fact that both signatures capture cell cycle and proliferation
is evident. It is well known that there are many genes whose
mRNA level correlates with proliferation, usually referred to as the
‘‘proliferation cluster’’, since they are all cluster together
[60,61,62]. Indeed both signatures contain genes from the
proliferation cluster, which enables them to approximately capture
the rate of proliferation. To test whether there are any additional
common pathways, we omitted from both lists the genes that were
highly correlated with cell proliferation. Those genes were
identified by calculating the Pearson correlation of their expression
with the expression of a gene known to be correlated with the rate
Table 1. The list of pathways whose hypergeometric p-value
is less than 0.05 and 0.1, without correcting for multiple
hypothesis testing.
Common pathways for p,0.05
Additional common
pathways for p,0.1
DNA metabolic process axon regeneration
DNA packaging cell cycle
DNA replication cellular component organization
DNA replication initiation chromatin assembly or disassembly
DNA strand elongation intracellular signaling cascade
DNA strand elongation during
DNA replication
mitotic cell cycle
DNA-dependent DNA replication negative regulation of translation
cell division nucleus localization
chromosome condensation response to hypoxia
chromosome organization second-messenger-mediated
signaling









Pathway Overlap of Breast Cancer Prognostic Lists
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17795of proliferation in the EMC-344 cohort [33,63]. To be on the safe
side, 3 attempts were made, each using a different proliferation
gene (either MKI67, TOP2A or CDK1, all of which appear in
three major papers discussing the members of the proliferation
cluster [60,61,62]). For each attempt, all the genes with Spearman
correlation of at least 50% were omitted from the list on which
they appeared. The genes that were omitted are listed in Table S4;
as can be seen, in all cases the common gene cyclin E2 was
omitted. The enrichment analyses described above were now
repeated for the filtered signatures.
The results of the enrichment analysis have changed dramati-
cally. No common pathways have passed any FDR (as a matter of
fact, no pathway was found in the reduced van’t Veer signature that
passed any FDR,1). Ignoring FDR corrections, only 1–2 common
pathways were found with p,0.05 (nucleus localization and in the
MKI67 case, also response to hypoxia), and 5 common pathways
for p,0.1. These overlaps were found to be not statistically
significant when comparing to the generated background distribu-
tion, as described above (p-values of 0.6–0.8). As before, the process
was repeated for the reduced GOBP list and MSigDB, as well as for
Wang’s complete 76 genes signature, yielding similar results. For
more details see Table S5 and Table S6.
One might claim that pathway enrichment is not an accurate
enough tool to answer the question whether two signatures capture
the same biological features. This might be true, but in this case
some other proof is necessary, and none has been presented yet.
For example, possibly the presence of even one single gene from a
pathway could suffice to capture a biological feature, at least to
some extent. Proliferation is a good example of such a possibility,
since apparently any gene picked from the proliferation cluster will
capture the proliferation rate. If this is indeed the case, our test
would find an insignificant enrichment, while in fact the pathway
is represented to some extent. It seems hard to believe, however,
that the expression level of one gene can capture the level of
activity or deregulation of more complex pathways.
Discussion
We presented a comprehensive analysis aimed at answering the
question whether the two outcome prediction signatures for early-
discovery breast cancer, of van’t Veer et al and Wang et al, capture
the same biological processes. We focused on these two signatures
since they were derived using machine learning approaches, with
minimal biological knowledge incorporated in the choice of the
predictive genes. While such an overlap between the biological
processes has been claimed or implied, very few studies have
actually tested this claim. We performed our tests in a way that on
the one hand did not ignore the problems of multiple testing, but on
the other hand took into account the dependent and nested nature
of the gene ontologies used. We found that the concordance of
enriched pathways between the two tested signatures is restricted to
capturing the cells’ proliferation rate. When proliferation-related
genes are deleted from the two lists, the number of pathways over
represented in both signatures does not exceed the number of such
pathways expected for two random gene lists.
Taken together, all the results obtained indicate that while there
is some common biology captured by the two signatures, it is very
limited: all the processes captured by both signatures are related to
cell proliferation.
To conclude on a constructive note, we do believe that an
expression-based prognostic method that is knowledge-based, i.e.
one that incorporates also well-established biological and clinical
information on relevant pathways, will be able to improve current
prediction capabilities.
Supporting Information
Table S1 Gene symbols of the genes in van’t Veer and Wang
signatures used in the analysis. The Wang signatures were
converted from the published probe sets by Affymetrix official
tables. The van’t Veer signature was converted from the published
probes using BLAST. The common gene cyclin E2 is highlighted.
(XLS)
Table S2 Enrichment analysis of each signature separately.
FDR controlled hypergeometric enrichment of van’t Veer
signature, Wang 60 gene ER+ signature and Wang 76 gene
signature, for GOBP annotations (both complete and filtered as
proposed by Wang et al), and MSigDB pathways. Additionally the
results of the TANGO analysis are attached. Pathways common
both to van’t Veer and one of Wang signatures are highlighted.
(XLS)
Table S3 Pathway overlap significance. The results of our
suggested random background model, estimating overlap signifi-
cance.
(XLS)
Table S4 The proliferation genes omitted. The genes were
selected according to correlation in expression in the EMC-344
cohort to the genes MKI67, TOP2A or CDK1.
(XLS)
Table S5 Enrichment analysis after omitting proliferation genes.
Hypergeometric enrichment of the signatures minus the genes that
correlated with proliferation.
(XLS)
Table S6 Pathway overlap significance after omitting prolifer-
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